SCHEMBL19633496

SCHEMBL19633496

CC(C)c1cc(OC2CCN(S(C)(=O)=O)CC2)ncn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 11/20 0.49
TDO2 P48775 1/20 0.42
RORC P51449 1/20 0.41
NAAA Q02083 1/20 0.41
CACNB4 O00305 3/20 0.41
CACNA1A O00555 3/20 0.41
CACNA1G O43497 3/20 0.41
CACNG3 O60359 3/20 0.41
CACNA1F O60840 3/20 0.41
CACNA1H O95180 3/20 0.41
CACNB3 P54284 3/20 0.41
CACNA2D1 P54289 3/20 0.41
CACNG7 P62955 3/20 0.41
CACNA1B Q00975 3/20 0.41
CACNA1D Q01668 3/20 0.41
CACNB1 Q02641 3/20 0.41
CACNG1 Q06432 3/20 0.41
CACNB2 Q08289 3/20 0.41
CACNA1S Q13698 3/20 0.41
CACNA1C Q13936 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21064126 0.90 GPR119 (0.48) GPR119TDO2RORCNAAACACNB4
SCHEMBL15830317 0.83 GPR119 (0.49) GPR119TDO2NAAACACNB4CACNA1A
SCHEMBL17303522 0.82 GPR119 (0.47) GPR119TDO2NAAACACNB4CACNA1A
SCHEMBL16217421 0.80 GPR119 (0.52) GPR119TDO2RORCNAAACACNB4
SCHEMBL19633442 0.79 NAAA (0.45) GPR119TDO2RORCNAAACACNB4
SCHEMBL17072682 0.75 GPR119 (0.43) GPR119TDO2RORCNAAACACNB4
SCHEMBL20252452 0.75 HDAC6 (0.38) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL19633720 0.74 GPR119 (0.46) GPR119TDO2RORC
SCHEMBL20252778 0.74 CACNB4 (0.43) GPR119TDO2RORCNAAACACNB4
SCHEMBL15830030 0.74 NAAA (0.48) GPR119TDO2RORCNAAACACNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10391089-B2 PRMT5 inhibitors and uses therof Epizyme, Inc. (US) 2019-08-27 US disclosed
US-10307413-B2 Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2019-06-04 US disclosed
US-20180162847-A1 PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF Epizyme, Inc. (US) 2018-06-14 US disclosed
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10391089-B2 PRMT5 inhibitors and uses therof PRMT5, PRMT1, PRMT6 GPR119 1373/4885TDO2 1585/4885RORC 2366/4885
US-10307413-B2 Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT3 GPR119 843/4885TDO2 2634/4885RORC 971/4885
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 GPR119 843/4885TDO2 2634/4885RORC 971/4885
US-20180162847-A1 PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF PRMT5, PRMT1, PRMT3 GPR119 1132/4885TDO2 3069/4885RORC 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.